Barrington Research Maintains Outperform on LeMaitre Vascular, Maintains $92 Price Target
Barrington Maintains LeMaitre Vascular(LMAT.US) With Buy Rating, Maintains Target Price $92
Barrington analyst Michael Petusky maintains $LeMaitre Vascular(LMAT.US)$ with a buy rating, and maintains the target price at $92.According to TipRanks data, the analyst has a success rate of 50.4%
Lemaitre Vascular's Growth Prospects Bolstered by Pricing Power and Strategic Expansion: A Buy Rating Review
Possible Bearish Signals With LeMaitre Vascular Insiders Disposing Stock
Is There Now An Opportunity In LeMaitre Vascular, Inc. (NASDAQ:LMAT)?
LeMaitre Vascular (NASDAQ:LMAT) Shareholders Have Earned a 25% CAGR Over the Last Five Years
LeMaitre to Participate at Upcoming Investor Conferences in September
Lake Street Maintains LeMaitre Vascular(LMAT.US) With Buy Rating, Maintains Target Price $105
Lake Street analyst Frank Takkinen maintains $LeMaitre Vascular(LMAT.US)$ with a buy rating, and maintains the target price at $105.According to TipRanks data, the analyst has a success rate of 46.7%
Lemaitre Vascular (LMAT) Gets a Buy From Lake Street
LeMaitre Vascular Financial Chief Pellegrino to Retire
LeMaitre Vascular CFO Retires, Joins Board of Directors
LeMaitre Vascular, Inc.: Will COnduct a Search for a Replacement CFO
LeMaitre Vascular, Inc.: Pellegrino to Remain as a Member of the Bd.
LeMaitre Vascular, Inc.: CFO Joseph Pellegrino, Jr. Will Retire From Co. Effective March 7, 2025
Express News | LeMaitre Vascular Inc: Announced That Joseph P. Pellegrino, Jr. Will Retire as an Employee of Co, Including as Chief Financial Officer
Express News | LeMaitre Vascular Inc - as of Aug 26, Reaffirms August 1, 2024 Financial Guidance Covering Q3 2024 and Full-Year 2024
JMP Securities Maintains Market Outperform on LeMaitre Vascular, Raises Price Target to $100
JMP Securities Maintains LeMaitre Vascular(LMAT.US) With Buy Rating, Raises Target Price to $100
JMP Securities analyst Daniel Stauder maintains $LeMaitre Vascular(LMAT.US)$ with a buy rating, and adjusts the target price from $77 to $100.According to TipRanks data, the analyst has a success
Lemaitre Vascular's Strong Financial Performance and Growth Potential Warrant a Buy Rating
Investors Appear Satisfied With LeMaitre Vascular, Inc.'s (NASDAQ:LMAT) Prospects